New Day Diagnostics Logo
  • Home
  • ColoHealth
    • Patient Information
    • Physician Information
  • CLIA Laboratory
  • Products
    • Colorectal Cancer
    • AxSpA
      • Patient Information
      • Physician Information
    • Celiac
    • H. pylori
    • Covid-Flu-RSV
    • COVID-19
    • Oncology Product Pipeline
      • ColoPlex Plus
      • Procare
  • About Us
    • Our Team
    • News
    • For Media

Case Study 2

CRO
Skills

Posted on

December 8, 2022

← Case Study 1 Case Study 3: ColoPlex →

Submit a Comment Cancel reply

You must be logged in to post a comment.

Topics

  • Articles
  • Company Details
  • News and Events
  • Products & Pipeline
  • Research & Development
  • Uncategorized

Recent Posts

  • Press Release: ColoHealth Blood Test Offers a Simpler First Step in Colorectal Cancer Screening–Now Direct-to-Consumer
  • Hepion Pharmaceuticals, New Day Diagnostics execute binding letter of intent
  • Press Release: Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
  • We’ve Been Busy, and the Press Has Noticed!
  • Knoxville lab launches blood test for colorectal cancer screening across US: ‘Life mission’

New Day Diagnostics Home

ColoHealth Home

Call Us: 865-299-6250
Email Us: [email protected]

Legal

Privacy

E-Library

BSI Medical Device Quality Assurance Mark
clia logo

CLIA#: 44D2184836

  • Follow
  • Follow
Knoxville Chamber of Commerce Member

Copyright © 2012-2024. All Rights Reserved.
Web Site usage is subject to New Day Diagnostics / EDP Biotech’s Web Site Usage and Privacy Policy. Copyright ©2024 New Day Diagnostics, All Rights Reserved. All other copyrights are owned by their respective owners.